Brooklyn Center, MN
Saturday, October 5, 2013
Earle Brown Heritage Center
6155 Earle Brown Dr.
Brooklyn Center, MN
Tack Room A
8:00 AM – 8:20 AM: Registration and Breakfast
8:20 AM – 12:20 PM: Interactive CPE Activity
Affecting over 1 million people in the United States, Parkinson’s Disease
(PD) is usually diagnosed in patients over 50 years of age and renders the majority of
patients disabled 10 to 15 years after disease onset. The cardinal manifestations resulting
from disease progression ultimately leave patients entombed within their own bodies,
often necessitating complex treatment regimens, frequent hospitalization, and
oftentimes institutionalization. Because substantial neuronal damage has already occurred
by the time patients are accurately diagnosed, timely recognition of symptoms
and referral to a neurologist are critical. Early diagnosis is particularly important since
disease-modifying therapies provide greater benefit to patients with early versus
advanced-stage PD. Managed care and community pharmacists play an integral role in
managing patients with PD by simplifying complex drug regimens, providing valuable
information for both clinicians and patients throughout therapy, managing adverse
events and drug interactions, and recognizing therapy-related problems early on in treatment.
This live activity is designed to provide community and managed care pharmacists
with the most up-to-date information on identification and management strategies for
patients with PD to enhance patient care.
|8:00 – 8:20 AM
||Registration and Breakfast
|8:20 – 8:35 AM
||Activity Overview and Goals
|8:35 – 9:40 AM
||Parkinson’s: The Disease
|9:40 – 9:55 AM
||Question & Answer Session
|9:55 – 10:10 AM
|10:10 – 11:20 AM
||Evidence, Cases, and Debate:
Breakout Sessions and Guided Discussions
|11:20 – 11:35 AM
|11:35 – 12:20 PM
||Concluding Remarks/Question & Answer Session
This educational activity will provide community and managed care pharmacists
education about the evolving strategies in treating and managing patients with PD,
as well as the management of complex dosing regimens and associated adverse events
and drug interactions.
This activity is designed for community and managed care
pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes
responsibility for the content, quality, and scientific integrity of this CPE activity. Upon
the conclusion of this activity, the participant should be able to:
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to
provide continuing education for pharmacists.
- RECOGNIZE signs and/or symptoms of early-stage PD.
- COMPARE strategies used for the management of early-stage PD.
- DISCUSS dose titration strategies used to maximize efficacy and tolerability in
early-stage PD and throughout the continuum of the disease.
- EMPLOY approaches to improve medication adherence in the PD patient.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy
Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will
provide a statement for 3.5 live contact hours credit (.35 CEUs). Successful completion includes attending the session, signing the attendance
sheet, and completion of the educational activity evaluation form. A statement of CE credit will be mailed within 4 weeks following successful
completion of the educational activity. ACPE Program Number: 0064-0000-13-209-L01-P.
Your CE credits will also be submitted electronically to the NABP. Pharmacists or pharmacy technicians with questions
regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website (www.nabp.net/programs/cpe-monitor/cpe-monitor-service) or contact NABP Customer Service: email@example.com or telephone 847-391-4406.
NABP e-PROFILE ID NUMBER: To receive credit for your participation in this course, all pharmacists must include
their NABP e-Profile ID number, along with their date and month of birth on the last page of the evaluation form.
Glen Farr, PharmD (Course Director)
Professor of Clinical Pharmacy and Associate Dean
University of Tennessee
College of Pharmacy
Michele A. Faulkner, PharmD
Associate Professor of Pharmacy
Practice and Neurology
Creighton University Schools of Pharmacy and Health Professions and Medicine
Michael W. Jann, PharmD,
FCP, FCCP, BCPP
Professor and Chair
Department of Pharmacotherapy
University of North Texas System College of Pharmacy
Fort Worth, TX
Sheldon J. Rich, RPh, PhD
President, SJR Associates, LLC
Palm Beach Gardens, FL
Clinical Assistant Professor
University of Michigan
Adjunct Assistant Professor
Wayne State University
Thomas E. Lackner, PharmD, CGP, FASCP
Director of Pharmacy Services
Eden Prairie, MN
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider
disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved
uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the course materials.
The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA
and the rules and regulations thereof. Please notify us if you have any special needs.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at firstname.lastname@example.org. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
There is no fee for this educational activity.